IL6 and plasma cell myeloma: Hao et al. demonstrated in myeloma that the secretion of IL-6, VEGF and cell-to-cell contact with microenvironment-derived stromal cells from patients with multiple myeloma (MM-BMSCs) significantly decreased the sensitivity of myeloma cells to bortezomib treatment.